Literature DB >> 26979635

Complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis: Risk factors for ICU admission and morbidity prognostic score.

Sylvain Malfroy1, Florent Wallet2, Delphine Maucort-Boulch3, Laurent Chardonnal2, Nicolas Sens2, Arnaud Friggeri2, Guillaume Passot4, Olivier Glehen4, Vincent Piriou2.   

Abstract

BACKGROUND AND OBJECTIVES: For patients suffering from peritoneal carcinomatosis, cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is the only curative option. We focused on severe complications in the postoperative course of HIPEC.
METHODS: We studied perioperative data from patients who underwent HIPEC between January 2010 and August 2011. Our primary objective was to identify perioperative risk factors for ICU admission. Our secondary objective was to identify patient that may be re-admitted to the ICU thanks to a prognostic score.
RESULTS: 122 patients underwent HIPEC. 32 presented severe adverse events (26.2%) and 7 died (5.7%). Reasons for ICU admission were septic shock in 28.1% of patients, hemorrhagic shock for 21.9%, hemodynamic instability for 15.6%, respiratory causes for 6.2% and post-operative acidosis for 6.2%. Vasopressors were required for 34% and 40.6% were mechanically ventilated.
CONCLUSION: Peritoneal cancer index, diaphragmatic peritonectomy, the need of vasopressive therapy, total volume of fluid leakage collected in drains and total volume of fluid therapy administered at day 1 reported on ideal body weight were the 5 significant variables that we combined to build a morbidity prognostic score. One patient over 4 is likely to present severe complications. A predictive morbidity score provide informative data for clinicians.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Intensive care unit admission; Peritoneal surface malignancies; Severe complications

Mesh:

Year:  2015        PMID: 26979635     DOI: 10.1016/j.suronc.2015.11.003

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  7 in total

1.  Risk of Intraoperative Hyperthermia and Outcomes in Adults Undergoing Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Authors:  Carlos E Guerra-Londono; Pascal Owusu-Agyemang; German Corrales; Marina M Rofaeil; Lei Feng; Keith Fournier; Juan P Cata
Journal:  Ann Surg Oncol       Date:  2021-10-26       Impact factor: 5.344

2.  Inflammatory response and optimalisation of perioperative fluid administration during hyperthermic intraoperative intraperitoneal chemotherapy surgery.

Authors:  Piet de Witte; Christien A de Witt; Johan L van de Minkelis; Djamila Boerma; H Frank Solinger; C Erik Hack; Peter Bruins
Journal:  J Gastrointest Oncol       Date:  2019-04

3.  Critical care management and intensive care unit outcomes following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

Authors:  Sumit Kapoor; Adel Bassily-Marcus; Rafael Alba Yunen; Parissa Tabrizian; Sabrine Semoin; Joseph Blankush; Daniel Labow; John Oropello; Anthony Manasia; Roopa Kohli-Seth
Journal:  World J Crit Care Med       Date:  2017-05-04

4.  Enhanced recovery after surgery (ERAS) in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): a cross-sectional survey.

Authors:  Geetu Bhandoria; Sohan Lal Solanki; Mrugank Bhavsar; Kalpana Balakrishnan; Cherukuri Bapuji; Nitin Bhorkar; Prashant Bhandarkar; Sameer Bhosale; Jigeeshu V Divatia; Anik Ghosh; Vikas Mahajan; Abraham Peedicayil; Praveen Nath; Snita Sinukumar; Robin Thambudorai; Ramakrishnan Ayloor Seshadri; Aditi Bhatt
Journal:  Pleura Peritoneum       Date:  2021-06-21

Review 5.  Molecular Mechanisms and Biomarkers Associated with Chemotherapy-Induced AKI.

Authors:  Letizia De Chiara; Gianmarco Lugli; Gianluca Villa; Valentina Raglianti; Faeq Husain-Syed; Fiammetta Ravaglia; Paola Romagnani; Elena Lazzeri
Journal:  Int J Mol Sci       Date:  2022-02-27       Impact factor: 5.923

6.  Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis.

Authors:  Ángela Bella; Leire Arrizabalaga; Claudia Augusta Di Trani; Assunta Cirella; Myriam Fernandez-Sendin; Celia Gomar; Joan Salvador Russo-Cabrera; Inmaculada Rodríguez; José González-Gomariz; Maite Alvarez; Álvaro Teijeira; José Medina-Echeverz; Maria Hinterberger; Hubertus Hochrein; Ignacio Melero; Pedro Berraondo; Fernando Aranda
Journal:  Oncoimmunology       Date:  2022-07-13       Impact factor: 7.723

7.  HIPEC-Induced Acute Kidney Injury: A Retrospective Clinical Study and Preclinical Model.

Authors:  Lukas F Liesenfeld; Benedikt Wagner; H Christian Hillebrecht; Maik Brune; Christoph Eckert; Johannes Klose; Thomas Schmidt; Markus W Büchler; Martin Schneider
Journal:  Ann Surg Oncol       Date:  2021-07-14       Impact factor: 5.344

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.